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Antithrombotic management of patients with atrial ﬁbrillation (AF) undergoing coronary stent-
ing is complicated by the need for anticoagulant therapy for stroke prevention and dual antipla-
telet therapy for prevention of stent thrombosis and coronary events. Triple antithrombotic
therapy, typically comprising warfarin, aspirin, and clopidogrel, is associated with a high risk of
bleeding. A modest-sized trial of oral anticoagulation with warfarin and clopidogrel without
aspirin showed improvements in both bleeding and thrombotic events compared with triple
therapy, but large trials are lacking. The RE-DUAL PCI trial (NCT 02164864) is a phase 3b, a
strategy of prospective, randomized, open-label, blinded-endpoint trial. The main objective is to
evaluate dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and
a P2Y12 inhibtor (either clopidogrel or ticagrelor) compared with triple antithrombotic therapy
with warfarin, a P2Y12 inhibtor (either clopidogrel or ticagrelor, and low-dose aspirin (for 1 or
3 months, depending on stent type) in nonvalvular AF patients who have undergone percutane-
ous coronary intervention with stenting. The primary endpoint is time to ﬁrst International
Society of Thrombosis and Hemostasis major bleeding event or clinically relevant nonmajor
bleeding event. Secondary endpoints are the composite of all cause death or thrombotic events
(myocardial infarction, or stroke/systemic embolism) and unplanned revascularization; death or
thrombotic events; individual outcome events; death, myocardial infarction, or stroke; and
unplanned revascularization. A hierarchical procedure for multiple testing will be used. The plan
is to randomize  2500 patients at approximately 550 centers worldwide to try to identify
new treatment strategies for this patient population.
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1 | INTRODUCTION
Long-term treatment with oral anticoagulants (OACs) is indicated in
patients with atrial ﬁbrillation (AF) for the prevention of stroke and
systemic embolism. Vitamin K antagonists (VKAs) such as warfarin
have been the mainstay of therapy for such patients on the basis of
evidence from placebo-controlled trials,1,2 in which VKAs were supe-
rior to aspirin and to dual antiplatelet therapy (clopidogrel and aspi-
rin).3,4 In contrast, for patients undergoing percutaneous coronary
intervention (PCI) with stent implantation, treatment with dual anti-
platelet therapy (with a P2Y12 inhibitor such as ticlopidine plus aspi-
rin) was superior to oral anticoagulation.5–8 The type of thrombosis
that develops may explain this differential beneﬁt: Stent thrombosis
(ST) and coronary events are usually caused by platelet-rich thrombi,
whereas in AF, low-shear stress thrombi can develop in the left
atrium, which is a less platelet-dependent process.
Many patients with AF also have ischemic heart disease,9 and
most guidelines have, until recently, recommended triple antithrom-
botic therapy, comprising an anticoagulant plus dual antiplatelet ther-
apy for such patients undergoing PCI. Not surprisingly, these potent
regimens are associated with very high rates of major bleeding. Sev-
eral large registries reported that the risk of major bleeding with triple
antithrombotic therapy is 3-fold to 4-fold higher than with OAC
alone or single antiplatelet therapy.10–13 In addition, major bleeding is
associated with an up to 5-fold increased risk of death following an
acute coronary syndrome (ACS).14,15 As such, the search is underway
for better treatment strategies that improve safety while preserving
efﬁcacy.
Two new promising approaches have emerged. First, non-VKA
oral anticoagulants (NOACs) have been developed, the ﬁrst being
dabigatran etexilate. This oral direct thrombin inhibitor was tested in
patients with nonvalvular AF in the Randomized Evaluation of Long-
term Anticoagulation Therapy (RE-LY) trial.16 RE-LY was a prospec-
tive, randomized, open-label (double-blind for the 2 dabigatran etexi-
late arms and open-label for warfarin), blinded-endpoint trial and
involved 18 113 patients. Dabigatran 150 mg twice daily, when
compared with warfarin, resulted in a lower rate of stroke or systemic
embolism (1.12% vs 1.72%, respectively) and a similar rate of major
bleeding events (3.40% vs 3.61%, respectively); dabigatran 110 mg
twice daily resulted in similar rates of stroke or systemic embolism
(1.54% vs 1.72%, respectively) and a lower rate of major bleeding
events (2.92% vs 3.61%, respectively). Both doses of dabigatran
reduced the risk of hemorrhagic stroke (150 mg, 0.10%; 110 mg,
0.12%; warfarin, 0.38%), whereas the 150-mg dose reduced the risk
of ischemic stroke.17 These beneﬁts of dabigatran over warfarin were
unchanged irrespective of whether patients had no concomitant
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antiplatelet therapy or if they had a single or even dual antiplatelet
therapy (Figure 1).18 As such, the direct comparison of dabigatran vs
warfarin has been made. There is, however, a need for prospective
data on the use of dabigatran as part of an antithrombotic strategy in
a stented population as compared with warfarin-antiplatelet strate-
gies, which have been evolving.
The other major development in this ﬁeld came from the rando-
mized What Is the Optimal Antiplatelet and Anticoagulant Therapy in
Patients With Oral Anticoagulation and Coronary Stenting (WOEST)
study.19 In this trial, 573 patients who were receiving anticoagulation
with VKAs (mostly for AF) and needed PCI were randomized to
standard triple antithrombotic therapy (anticoagulant, clopidogrel, and
aspirin) vs dual antithrombotic therapy (anticoagulant and clopido-
grel). The study showed that dual antithrombotic therapy signiﬁcantly
reduced the risk of bleeding and was also associated with a lower risk
of death or thrombotic events than was triple antithrombotic ther-
apy.19 Data from registries support the WOEST ﬁndings.19,20 More
recently, the ﬁndings from the open-label ISAR-TRIPLE trial,21 which
involved 614 patients with an indication for OAC who were under-
going drug-eluting stent (DES) implantation, support a limited dura-
tion (6 weeks vs 6 months) of triple antithrombotic therapy.22
On the basis of these developments, a recent survey found that
clinicians are interested in using NOACs as well as adopting a strat-
egy of single antiplatelet therapy.23 Indeed, a shift in practice guide-
lines is also emerging whereby the 2014 American Heart
Association/American College of Cardiology/Heart Rhythm Society
guidelines state that in patients with AF who underwent a recent PCI
and have a CHA2DS2-VASc (congestive heart failure, hypertension,
age ≥75 y, diabetes mellitus, stroke/transient ischemic attack, vascu-
lar disease, age 65–74 y, sex category [women]) score ≥2, it may be
reasonable to use clopidogrel (75 mg once a day) concurrently with
an OAC but without aspirin.24 However, evidence supporting this
recommendation is limited (class IIb, level of evidence B). The
European Society of Cardiology, along with various other groups,
released a joint consensus statement that also recommends dual
antithrombotic therapy as an option in many patient groups, based
on bleeding and thrombotic risk.25 However, these recommendations
are complex, derived from a single small trial,19 and therefore rela-
tively weak. Consequently, a single, 3-stage algorithm, applicable to a
broad range of patients with coronary artery disease (CAD), has been
proposed.26
Randomized Evaluation of Dual Antithrombotic Therapy With
Dabigatran vs Triple Therapy With Warfarin in Patients With Non-
valvular Atrial Fibrillation Undergoing Percutaneous Coronary Inter-
vention (RE-DUAL PCI) is a large, prospective, randomized trial that
aims to test dual antithrombotic therapy and triple antithrombotic
therapy with adequate power. The hypothesis is that, in patients with
nonvalvular AF who have undergone PCI with stenting, dabigatran
(110 or 150 mg twice daily) and clopidogrel or ticagrelor are nonin-
ferior to warfarin, clopidogrel or ticagrelor, and aspirin with respect
to major bleeding events or clinically relevant nonmajor bleeding
events over the duration of the trial. Of note, the reference arm is tri-
ple antithrombotic therapy for only 1 month or 3 months (depending
on stent type), after which it too reverts to dual antithrombotic ther-
apy, in keeping with the evolving guideline recommendations on tri-
ple antithrombotic therapy.
2 | METHODS
RE-DUAL PCI is a multicenter, prospective, randomized, open-label,
blinded-endpoint, active-comparator, phase 3b, event-driven clinical
trial that plans to enroll  2500 patients at approximately 550 sites
in 41 countries (see Appendix,). Patients are currently being recruited.
2.1 | Study Population
Study entry criteria are summarized in Table 1. Brieﬂy, eligible adults
have nonvalvular AF, are either treatment-naïve or receiving an OAC,
have an ACS or stable CAD, and were successfully treated with PCI
with bare-metal stent (BMS) or DES implantation. Nonvalvular AF
could be paroxysmal, persistent, or permanent, but not secondary to
a reversible disorder (eg, myocardial infarction [MI], pulmonary embo-
lism, recent surgery, pericarditis, or thyrotoxicosis) unless long-term
OAC is planned. Patients with implanted heart valves, severe renal
insufﬁciency, and other major comorbidities will be excluded.
This study will be conducted in compliance with institutional
review boards/institutional ethics committees, the principles laid
down in the last revision of the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation Good Clinical Practice guide-
lines, and local laws and regulations relevant to the use of new
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FIGURE 1 Data from the RE-LY trial18:
Rates of major bleeding of warfarin vs
dabigatran, with either no background
antiplatelet therapy, single or dual
antiplatelet therapy. As shown, in each
group, the rates are higher as the number
of antiplatelet agents increases, but rates
tend to be highest with warfarin, then
dabigatran 150 mg twice daily, and then
dabigatran 110 mg twice daily.
Abbreviations: RE-LY, Randomized
Evaluation of Long-term Anticoagulation
Therapy.
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therapeutic agents. All patients will provide written informed
consent.
2.2 | Treatment Protocol
The trial schema is shown in Figure 2. Patients with nonvalvular AF
undergoing planned PCI will be identiﬁed as possible candidates dur-
ing a prescreening period. All antithrombotic treatment for the PCI
will be given according to standard guidelines, which call for loading
doses of P2Y12 inhibitors and aspirin.
27,28 Formal screening will be
initiated after successful PCI. Eligible patients who consent to partici-
pate will be randomized to 1 of 3 treatment arms: (1) dabigatran etex-
ilate 110 mg twice daily plus either clopidogrel or ticagrelor (“110 mg
DE-DAT”); (2) dabigatran etexilate 150 mg twice daily plus either clopi-
dogrel or ticagrelor (“150 mg DE-DAT”); or (3) warfarin plus one of clo-
pidogrel or ticagrelor, plus aspirin ≤100 mg once daily (“warfarin–triple
antithrombotic therapy”). In the warfarin arm, aspirin will be discon-
tinued after 1 month in patients implanted with a BMS and after
3 months in patients implanted with a DES, thus becoming a dual
antithrombotic therapy strategy for most of the trial duration.
Randomization will be stratiﬁed in permuted blocks, dynamically
stratiﬁed by aged (<80 or ≥80 years; <70 or ≥70 years for patients
enrolled in Japan) and region (United States, Japan, and rest of the
world). Patients age <80 years (for Japan <70 years) and all patients
in the United States will be randomly assigned to 110 mg DE-DAT,
150 mg DE-DAT, or warfarin–triple antithrombotic therapy in a 1:1:1
ratio. Non-US patients aged ≥80 years (for Japan ≥70 years) will be
assigned to 110 mg DE-DAT or warfarin–triple antithrombotic ther-
apy in a 1:1 ratio (to be consistent with the labeling of dabigatran in
elderly patients in non-US countries). The ﬁrst dose of the study drug
will be administered ≥6 hours after sheath removal and after hemo-
stasis has been assured, up to 120 hours after successful PCI (but
TABLE 1 Eligibility Criteria
Inclusion Criteria
• Age ≥18 years
• Nonvalvular AF: paroxysmal, persistent, or permanent, but not secondary to a reversible disorder (eg, MI, PE, recent surgery, pericarditis, or
thyrotoxicosis) unless long-term OAC is planned
• Receiving OAC treatment (warfarin, another VKA or non-VKA OAC) or treatment naïve prior to PCI
• ACS (STEMI/NSTEMI/UA) successfullya treated by PCI and stenting (BMS or DES) or stable CAD with ≥1 lesion eligible for PCI that was
successfullya treated by electiveb PCI and stenting (BMS or DES)
• Ability to provide informed consent in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local
legislation and/or regulations
Exclusion Criteria
• Mechanical or biological heart valve prosthesis
• Cardiogenic shock during current hospitalization
• Use of ﬁbrinolytic agents within 24 hours of randomization that could put patient at high risk of bleeding
• Stroke or major surgery within 1 month prior to screening visit
• Receipt of, or on waiting list for, an organ transplant
• History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding, unless causative factor has been permanently eliminated or
repaired
• GI hemorrhage within 1 month prior to screening, unless cause has been permanently eliminated
• Major bleeding episode,c including life-threatening bleeding episode,d within 1 month prior to screening visit
• Hemorrhagic disorder or bleeding diathesis (eg, von Willebrand disease, hemophilia A or B or other hereditary bleeding disorder, history of
spontaneous intra-articular bleeding or of prolonged bleeding after surgery/intervention)
• Anemia (Hb <10 g/dL) or thrombocytopenia (including heparin-induced; platelet count <100 × 109/L) at screening
• Severe renal impairment (estimated CrCl <30 mL/min, calculated by Cockcroft-Gault equation) at screening
• Active liver disease (ie, ≥1 of prior and persistent ALT, AST, or AP >3× ULN); known active hepatitis A, B, or C
• Recent malignancy or radiation therapy (≤6 months) unless estimated life expectancy >36 months
• Need for continued treatment with systemic ketoconazole, itraconazole, posaconazole, cyclosporine, tacrolimus, dronedarone, rifampicin, phenytoin,
carbamazepine, St. John’s wort, or any cytotoxic/myelosuppressive therapy
• Need for continuous treatment with NSAIDs
• Known allergy to dabigatran etexilate or capsule excipients, or warfarin tablets or excipients
• Contraindication to OAC treatment, clopidogrel, ticagrelor, or ASA
• Premenopausal (last menstruation ≤1 year prior to screening) and: pregnant or breast feeding; not surgically sterile; of childbearing potential and not
(planning to continue) practicing an acceptable method of birth control throughout the trial
Abbreviations: ACS, acute coronary syndrome; AF, atrial ﬁbrillation; ALT, alanine aminotransferase; AP, alkaline phosphatase; ASA, aspirin (acetylsalicylic
acid); AST, aspartate transaminase; BMS, bare-metal stent; CAD, coronary artery disease; CrCl, creatinine clearance; DES, drug-eluting stent; GI, gastroin-
testinal; Hb, hemoglobin; MACE, major adverse cardiac events; MI, myocardial infarction; NSAID, nonsteroidal anti-inﬂammatory drug; NSTEMI, non–ST-
segment elevation myocardial infarction; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; PE, pulmonary embolism; STEMI, ST-
segment elevation myocardial infarction; UA, unstable angina; ULN, upper limit of normal; VKA, vitamin K antagonist.
aAchievement of <30% residual diameter stenosis of the target lesion assessed by visual inspection or quantitative coronary angiography and no in-
hospital MACE (MI or repeat coronary revascularization of the target lesion). b Indication for elective PCI should be based on recent guidelines.27,28 c Hb
reduction of ≥2 g/dL, transfusion of ≥2 units of blood, or symptomatic bleeding in a critical area or organ. d Symptomatic intracranial bleeding; bleeding
with Hb decrease of ≥5 g/dL; or bleeding requiring transfusion of ≥4 units of blood, inotropic agents, or surgery.
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preferably within 72 hours). Patients may receive bridging therapy
with a parenteral anticoagulant according to local practice before
switching to the trial medication.
The dose of warfarin will be adjusted to ensure the patient’s
international normalized ratio (INR), measured locally, is maintained at
2.0 to 3.0, ideally targeted at 2.0 to 2.5. For patients initiating warfa-
rin, INR will be measured at least every 2 weeks for the ﬁrst 3 months
to obtain target INR as soon as possible to avoid overdosing or
underdosing. The quality of warfarin therapy for each patient will be
assessed by reporting the number of INR values within the ranges of
2.0 to 3.0 and 2.0 to 2.5, as well as those above and below these
ranges. The Rosendaal method29 will be used to provide another
evaluation of percentage of time a patient’s INR is within these target
ranges. Good-quality anticoagulation control with VKAs, with atten-
tion to the time in therapeutic range, will be undertaken, given the
relationship of time in therapeutic range to thromboembolism and
bleeding.30
All patients will receive either clopidogrel 75 mg once daily or
ticagrelor 90 mg twice daily according to the local label for
≥12 months following randomization, with the choice of agent at
the discretion of the investigator. Discontinuation of clopidogrel or
ticagrelor or switching to aspirin (≤100 mg once daily) after
12 months of treatment will also be at the discretion of the investi-
gator, allowing investigators to discontinue antiplatelet therapy as
suggested by a European consensus.25 The use of prasugrel is not
allowed based on a study showing that prasugrel was associated
with a 4-fold increase in major bleeding when used in the setting of
triple antithrombotic therapy in patients with evidence of clopido-
grel resistance.31
Regarding aspirin therapy, all patients will have received aspirin
at the time of PCI and daily before randomization. Patients rando-
mized to either dabigatran arm will discontinue aspirin at the time of
randomization before administration of trial drug. Patients rando-
mized to receive warfarin will only receive aspirin (≤100 mg once
daily) for 1 month or 3 months for those implanted with a BMS or
DES, respectively. The duration of aspirin treatment for DES patients
was discussed extensively by the executive steering committee and
was a balance of using triple antithrombotic therapy for a reasonable
duration for efﬁcacy, but recognizing the desire to reduce bleeding
over time. In the absence of anticoagulation, the recent dual antipla-
telet therapy trial showed beneﬁt of 30 months over 12 months of
dual antiplatelet therapy,32 and one might therefore consider longer
triple therapy, but the ongoing risk of bleeding would limit this.
All patients will remain on study treatment until the last patient
randomized has received a minimum of 6 months of study treatment.
The maximum treatment duration is expected to be 30 months,
although the study may conclude earlier if an adequate number of
events is reported, or it may conclude later (or enroll additional
FIGURE 2 Treatment schema. Patients who meet the study entry criteria will be assigned to 1 of 3 treatment arms. First administration of
study treatment will be at visit 2, between 6 hours after sheath removal and up to 120 hours after successful PCI with stenting. All patients will
remain on study treatment until the last patient entered has completed ≥6 months of study treatment. Patients will have a 4-week follow-up
visit. Telephone follow-ups will be conducted at 15, 21, and 27 months (not shown). Dabigatran etexilate dosage is 110 mg twice daily or
150 mg twice daily; clopidogrel dosage is 75 mg once daily; ticagrelor dosage is 90 mg twice daily; warfarin dosage is 1 mg, 3 mg, or 5 mg once
daily, individually managed by study investigators to a target INR of 2.0 to 3.0; and ASA dosage is ≤100 mg once daily. Abbreviations: ASA,
aspirin (acetylsalicylic acid); b.i.d., twice a day; BMS, bare-metal stent; DES, drug-eluting stent; INR, international normalized ratio; PCI,
percutaneous coronary intervention; q.d., once a day; R, randomization; US, United States.
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patients) if more time (or patients) may be needed to observe the
minimum number of required events.
Some local amendments were incorporated. In the United
States, the US Food and Drug Administration (FDA) requires that
genetic testing for CYP2C19 be carried out, in accordance with the
US label for clopidogrel. A pharmacokinetic substudy will be carried
out in Germany. In Japan, an age cutoff of 70 years was chosen
for the 150-mg dose of dabigatran, in accordance with local guide-
line recommendations, regulatory requirements, and clinical prac-
tice. In the initial protocol, a sample size of 8520 was planned to
allow for an efﬁcacy primary endpoint of thrombotic events; the
feasibility of enrolling patients in a timely fashion did not
allow this.
2.3 | Study Endpoints
The primary endpoint is time to ﬁrst major (deﬁned as per the Inter-
national Society of Thrombosis and Hemostasis major criteria33) or
clinically relevant nonmajor bleeding event. A clinically relevant non-
major bleeding event is deﬁned as a clinically overt bleed that does
not meet the criteria for a major bleed but prompts a clinical
response, in that it leads to ≥1 of the following: hospital admission
for bleeding; physician-guided medical or surgical treatment for
bleeding; and physician-guided change, interruption, or discontinua-
tion of study drug.
The secondary endpoints (assessed by time to ﬁrst event) are the
composite of death or thrombotic event, comprising all-cause death
(cardiovascular, noncardiovascular, and undetermined), MI, or stroke/
systemic embolism, and unplanned revascularization (PCI/coronary
artery bypass grafting); death or thrombotic event; individual out-
come events (all-cause death, MI, stroke, systemic embolism, ST); the
composite endpoint of death, MI, or stroke; and unplanned revascu-
larization by PCI or coronary artery bypass grafting.
Endpoints will be adjudicated by an independent committee
blinded to treatment assignment. Subgroup analyses are planned
across major subgroups by medical history, baseline medication use,
baseline risk of stroke and/or bleeding, type of stent, and clinical
presentation at baseline.
2.4 | Statistical Design and Analysis
This study is designed to test 2 safety hypotheses in patients with
nonvalvular AF who have undergone successful PCI with stenting:
(1) 110 mg DE-DAT is noninferior to warfarin–triple antithrombotic
therapy with respect to major bleeding events/clinically relevant non-
major bleeding events over the duration of the trial; and (2) 150 mg
DE-DAT is noninferior to warfarin–triple antithrombotic therapy with
respect to major bleeding events/clinically relevant nonmajor bleed-
ing events over the duration of the trial.
To control the type I error rate at a 1-sided 0.025 level, a hier-
archical procedure for multiple testing will be used to test the
safety hypotheses, as outlined in Table 2; additional testing for
safety and efﬁcacy endpoints will be included. If any of the steps
fails to meet statistical signiﬁcance, the testing procedure will stop
and subsequent tests will not be performed. The noninferiority mar-
gin used for major bleeding events/clinically relevant nonmajor
bleeding events will be 1.38 (on the relative hazard ratio
[HR] scale), as was used by the FDA for ximelagatran, apixaban, riv-
aroxaban, and dabigatran to preserve ≥50% of the relative reduction
(on the log scale) in the risk of stroke or systemic embolism associ-
ated with warfarin in 6 previous randomized trials.34 The same non-
inferiority margin has been applied to major bleeding events/
clinically relevant nonmajor bleeding events, as it was considered
the most clinically relevant available reference in the absence of
any other type of data. The upper bound of the Wald conﬁdence
interval (CI) of the HR of DE-DAT vs warfarin-triple antithrombotic
therapy (1-sided 97.5%) will be compared with this noninferiority
margin for the noninferiority testing.
The study will employ a time-to-ﬁrst-event analysis. The pri-
mary endpoint will be compared across treatments using the strati-
ﬁed Cox proportional hazards regression model stratiﬁed by age
(<80 or ≥80 years [Japan, <70 or ≥70 years]). The primary analysis
will be performed under the intent-to-treat framework on the full
analysis set, which will include all randomized patients, regardless of
whether they receive treatment. The robustness of the primary ana-
lyses will be assessed by an on-treatment analysis, which will only
count events that occur while a patient is taking study medication
(including the residual effect period of 6 days).
TABLE 2 Hierarchical Procedure for Multiple Testing (Safety Hypotheses)
Step Test
1 Noninferiority of 110 mg DE-DAT to warfarin–triple antithrombotic therapy in major bleeding events/clinically relevant nonmajor bleeding
events
2 Noninferiority of 150 mg DE-DAT to warfarin–triple antithrombotic therapy in major bleeding events/clinically relevant nonmajor bleeding
events
3 Noninferiority of 150 mg DE-DAT and 110 mg DE-DAT combined to warfarin–triple antithrombotic therapy in death or thrombotic event and
unplanned revascularization by PCI/CABG
4 Superiority of 110 mg DE-DAT to warfarin–triple antithrombotic therapy in major bleeding events/clinically relevant nonmajor bleeding events
5 Noninferiority of 150 mg DE-DAT and 110 mg DE-DAT combined to warfarin–triple antithrombotic therapy in death or thrombotic event
6 Superiority of 150 mg DE-DAT to warfarin–triple antithrombotic therapy in major bleeding events/clinically relevant nonmajor bleeding
events.
If any of the above steps fails to meet statistical signiﬁcance, the testing procedure will stop and subsequent tests will not be performed.
Abbreviations: CABG, coronary artery bypass grafting; DE-DAT, dabigatran etexilate dual antithrombotic therapy; PCI, percutaneous coronary
intervention.
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The trial data are reviewed by an independent data monitoring
committee, which will be allowed to recommend stopping the study
(or an arm in the study) for safety. In addition, the chair of the data
monitoring committee will review unblinded data every 2 months, or
more frequently if needed, to ensure the safety of patients in the
trial.
The overall sample size is driven by the noninferiority compari-
son of major bleeding events/clinically relevant nonmajor bleeding
events between 110 mg DE-DAT or 150 mg DE-DAT and
warfarin–triple antithrombotic therapy. With α = 0.025 (1-sided)
and assuming 14% of patients with ≥1 event at 1 year, 334 patients
with ≥1 major bleeding event/clinically relevant nonmajor bleeding
event in each pair of treatment groups (ie, 167 patients with major
bleeding events/clinically relevant nonmajor bleeding events per
treatment group) are required to achieve 83.6% power for this end-
point, yielding a ﬁnal sample size estimated at 834 patients in each
treatment group (ie, 2502 randomized patients in total). Therefore,
approximately 500 patients with ≥1 major bleeding event/clinically
relevant nonmajor bleeding event are required in total across the
3 treatment groups. An estimation of the anticipated power for the
thrombotic endpoint analysis in the hierarchical testing, evaluating
noninferiority with the same margins as the primary endpoint (NI
margin 1.38) of the combined 2 dabigatran groups vs warfarin, is
approximately 70%.
3 | DISCUSSION
In patients with AF undergoing PCI, the issue of how to balance the
need for multiple antithrombotic drugs for prevention of thrombosis
against the high risk of bleeding has remained a conundrum for clini-
cians for the past decade. A recent registry analysis35 as well as a
survey23 found that physician practices vary widely regarding the
perceived optimal antithrombotic strategy.
A wide spectrum of strategies can be considered for use in this
population (Figure 3). With many different P2Y12 inhibitors available
in current practice, and 4 NOACs, some with different doses, more
than 25 possible drug combinations are available. In addition, differ-
ent durations of antiplatelet therapy can be used, leading to hundreds
of possible treatment strategies. Although this variety offers great
options for patients and physicians, very few data support any of
them other than the standard triple antithrombotic therapy with aspi-
rin, clopidogrel, and warfarin. As noted above, antiplatelet monother-
apy is not sufﬁcient for stroke prevention, nor is dual antiplatelet
therapy alone (although this has not been tested with the more
potent drugs). On the other end of the spectrum, use of triple antith-
rombotic therapy for 1 year has an unacceptable increased risk of
bleeding.13,20,36
The RE-DUAL PCI trial aims to study several new strategies for
antithrombotic treatment in these patients, and 3 regimens across
the spectrum of intensity have been selected. The 2 dual antithrom-
botic therapy regimens will include a NOAC—dabigatran etexilate—at
both of the doses shown to be effective and approved (worldwide).
These doses of dabigatran offer a sufﬁcient level of anticoagulation,
providing a similar (110 mg) or superior (150 mg) effect to warfarin
for stroke prevention.16 RE-DUAL PCI will not seek to re-prove the
efﬁcacy of dabigatran for stroke prevention, but rather will look at
the overall balance of safety and efﬁcacy as part of the dual antith-
rombotic strategy.
The 2 dabigatran arms in RE-DUAL PCI will fully adopt the dual
antithrombotic therapy approach, with immediate discontinuation of
aspirin at the time of randomization before administration of trial
drug. As such, RE-DUAL PCI will be a large follow-up study to test a
WOEST19-like strategy in an adequately powered manner. With
FIGURE 3 Options for
antithrombotic regimens in
patients with AF undergoing PCI.
Additional nuances of these
strategies could be applied by
changing the duration of
antiplatelet therapy. Abbreviations:
AF, atrial ﬁbrillation; NOAC, non–
vitamin K antagonist oral
anticoagulant; PCI, percutaneous
coronary intervention.
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dabigatran, the risk of MI was not statistically higher than with warfa-
rin in RE-LY, whereas all thrombotic events (MI, stroke/embolism,
revascularization, unstable angina, or cardiac death) were statistically
signiﬁcantly lower with dabigatran 150 mg.37 In addition, the recent
FDA analysis found no increase in MI.38 Of note, as patients will have
received standard doses of aspirin for the PCI, the antiplatelet effect
of aspirin will remain for 5 to 7 days, covering the early post-PCI
period, when patients are at highest risk of thrombotic events.
For the control arm, patients start with standard triple antithrom-
botic therapy (warfarin, aspirin, and either clopidogrel or ticagrelor),
but this will be altered in line with newer data and guidelines to lead
to an “enhanced” standard of care. The duration of dual antiplatelet
therapy has been shortened, in keeping with the overall trend sug-
gested by WOEST19; but instead of stopping the P2Y12 inhibitor
(as has been the standard in prior guidelines and practice), aspirin will
be stopped. As such, the triple antithrombotic therapy strategy will
revert to a dual antithrombotic therapy approach for most of the
study period.
All 3 arms in RE-DUAL PCI will allow the use of ticagrelor, given
the beneﬁts seen in reducing risk of death and the lack of increase in
major bleeding, when analyzed in intent-to-treat, compared with clo-
pidogrel in the Platelet Inhibition and Platelet Outcomes (PLATO)
trial.39 It should also be noted that there are sparse data on the use
of ticagrelor in nonvalvular AF patients who have undergone PCI. As
such, patients will be monitored carefully, with special focus by the
data monitoring committee throughout the trial.
3.1 | Prior Studies Supporting Dual
Antithrombotic Therapy
The concept of a dual antithrombotic therapy approach has support
from previous studies in terms of efﬁcacy and safety. Indeed, because
blockade of P2Y12 receptor–mediated signaling with clopidogrel is
associated with greater platelet-inhibitory effects than
cyclooxygenase-1 inhibition with aspirin, as well as the established
role of P2Y12 receptor blockade on recurrent thrombotic events, clo-
pidogrel might be expected to be more effective than aspirin at redu-
cing risk of ST, with a potentially lower rate of gastrointestinal
bleeding as well.40 A few retrospective cohorts have observed a
lower incidence of ST with clopidogrel plus warfarin dual antithrom-
botic therapy,13,20,41 and clopidogrel, aspirin, and warfarin triple
antithrombotic therapy,42 compared with warfarin and aspirin dual
antithrombotic therapy.
The WOEST study19 demonstrated lower rates of bleeding and
ischemic events for patients receiving dual antithrombotic therapy
(warfarin and clopidogrel) compared with triple antithrombotic ther-
apy (warfarin, clopidogrel, and aspirin). One-year follow-up data
showed that bleeding episodes were observed in 19.4% of patients
receiving dual antithrombotic therapy vs 44.4% receiving triple
antithrombotic therapy (HR: 0.36, 95% CI: 0.26, 0.50, p < 0.0001).
However, this study was not powered to assess efﬁcacy and can
therefore only be considered hypothesis-generating. In the ISAR-
TRIPLE study,21 in which patients were randomized to 6 weeks or
6 months of clopidogrel on top of aspirin and OAC after DES implan-
tation, no difference was apparent between groups in the primary
endpoint of death, MI, ST, stroke, or Thrombolysis In Myocardial
Infarction major bleeding (HR: 1.14, 95% CI: 0.68, 1.91, p = 0.63) at
9-month follow-up. Furthermore, there were no differences in the
combined secondary endpoint (cardiac death, MI, ST, or ischemic
stroke; HR: 0.93, 95% CI: 0.43, 2.05, p = 0.44) or in Thrombolysis In
Myocardial Infarction major bleeding (HR: 1.35, 95% CI: 0.64, 2.84,
p = 0.87). These data suggest that physicians should balance patients’
risk of ischemic events against their bleeding risk when selecting the
shorter or longer duration of triple therapy.
With these emerging provocative data, clinical guidelines24 are
already being adjusted, with dual antithrombotic therapy being given
a class IIb recommendation in this patient population. In the latest
European Society of Cardiology consensus statement,25 dual antith-
rombotic therapy is recommended over triple antithrombotic therapy
in AF patients with low stroke risk, high bleeding risk, stable CAD,
and PCI; is an option in most other situations; but is not suggested as
an early treatment option in patients with low bleeding risk and an
ACS. However, prospective clinical data with any new dual antith-
rombotic therapy or triple antithrombotic therapy regimen with dabi-
gatran etexilate or other NOACs in nonvalvular AF patients
undergoing PCI would be helpful.41
4 | CONCLUSION
RE-DUAL PCI is designed to provide clinicians with robust, much-
needed information regarding treatment for nonvalvular AF patients
who have undergone PCI with stenting.
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